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Abstract
Retinoic acid (RA) has been approved for the differentiation therapy of neuroblastoma (NB). Previous work revealed a
correlation between glucose-regulated protein 75 (GRP75) and the RA-elicited neuronal differentiation of NB cells. The
present study further demonstrated that GRP75 translocates into the nucleus and physically interacts with retinoid
receptors (RARa and RXRa) to augment RA-elicited neuronal differentiation. GRP75 was required for RARa/RXRa-mediated
transcriptional regulation and was shown to reduce the proteasome-mediated degradation of RARa/RXRain a RA-
dependent manner. More intriguingly, the level of GRP75/RARa/RXRa tripartite complexes was tightly associated with the
RA-induced suppression of tumor growth in animals and the histological grade of differentiation in human NB tumors. The
formation of GRP75/RARa/RXRa complexes was intimately correlated with a normal MYCN copy number of NB tumors,
possibly implicating a favorable prognosis of NB tumors. The present findings reveal a novel function of nucleus-localized
GRP75 in actively promoting neuronal differentiation, delineating the mode of action for the differentiation therapy of NB
by RA.
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Introduction
Neuroblastoma (NB) is the most common and deadly cancer in
patients who are identified during the first year of life, and are
often diagnosed as an aggressive and metastatic disease that leads
to high mortality [1]. Despite the noted improvement in the
overall outcome in patients with NB, the 5-year survival rates
among children with high-risk NB have only improved slightly.
This result is mainly attributed to the fact that key molecular
pathways controlling NB tumorigenesis remain elusive.
Current treatments for NB include a combination of chemo-
therapy, surgery, radiation, bone marrow transplantation, immu-
notherapy, and differentiating agents [2]. NB is the only pediatric
cancer treated with differentiation reagents as the first-line of
defense [2]. One of the most potent differentiation inducers for NB
is retinoic acid (RA) [3,4]. The results of independent trials have
consistently shown that the administration of RA significantly
improves the overall survival rates after bone-marrow transplan-
tation [5,6,7]. Consistent with these findings, NB cells treated with
all-trans RA at doses used clinically display evident neuronal
differentiation and reduced proliferation [8]. Therefore, the
elucidation of molecular mechanisms underlying RA-induced
neuronal differentiation in NB could pave the way for the
development of novel therapeutic strategies for NB.
RA-elicited signaling is primarily mediated by retinoid receptors
[9]. The retinoid receptors can be categorized into two
subfamilies: retinoic acid receptors (RARs) and retinoid X
receptors (RXRs). Upon binding RA, the ligand-bound RAR/
RXR heterodimers undergo a conformational change, causing
their translocation to the nucleus, where they act as transcription
factors targeting retinoic acid responsive elements (RARE) within
the promoters of genes involved in differentiation and growth
arrest [10,11]. Recent studies show that the activity of RA
receptors can be regulated by posttranslational modifications, such
as phosphorylation and ubiquitination [12]. Moreover, the ligand-
induced transactivation of RAR/RXR heterodimers could also be
modulated by various adaptor proteins in the nucleus [13].
Glucose-regulated protein 75 (GRP75) was first identified as a
member of the Hsp70 family that could function in multiple
subcellular compartments [14]. Accumulated evidence has
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26236demonstrated the versatility of GRP75 in regulating cellular stress
responses, mitochondrial homeostasis, intracellular trafficking,
antigen presenting, cell proliferation, differentiation, and tumor-
igenesis [15]. Previous work from our group demonstrated that
GRP75 is upregulated in RA-treated NB cells and in NB patients
with favorable prognostic outcome [16]. The present study further
investigates the possible role of altered GRP75 expression in the
regulation of RA-elicited neuronal differentiation in NB.
Results
Nuclear translocation of GRP75 is significantly enhanced
upon retinoic acid-induced neuronal differentiation in
neuroblastoma cells
We previously demonstrated that GRP75 expression is
significantly increased in retinoic acid-treated NB cells and is
associated with a favorable prognosis in NB patients [16]. In the
present study, immunofluorescence confocal microscopy revealed
that GRP75 was highly enriched in the nuclei of RA-treated NB
cells compared to untreated cells. The cross-sectional views of
stacked images unambiguously revealed that the nuclear translo-
cation of GRP75 was significantly enhanced for an approximately
4-fold increase in RA-treated cells compared to DMSO-treated
controls (Figure S1A-C). To further confirm the RA-induced
nuclear localization of GRP75, the levels of GRP75 in both
nuclear and cytoplasmic fractions prepared from RA- and
DMSO-treated NB cells were determined by Western blotting,
and the results showed a dramatic increase in nuclear GRP75 in
RA-treated cells compared to control cells, while the cytosolic
pools of GRP75 remained unchanged in response to RA treatment
(Figure S1D). We also found that RA can induce the nuclear
translocation of GRP75 in a dose-dependent manner (Figure S13).
This RA-induced nuclear translocation of GRP75 was indepen-
dently confirmed in two separate NB cell lines (SK-N-DZ and SK-
N-SH NB, Figure S12). Together, the present findings provide the
first direct evidence that GRP75 can be localized to the nucleus,
where it potentially plays a critical role in the RA-elicited neuronal
differentiation of NB cells.
The interaction between nuclear GRP75 with retinoic
acid receptors is significantly enhanced in differentiated
NB cells
RA primarily binds to RARa/RXRa heterodimers to transduce
its downstream signaling [17]. It is therefore possible that the
nucleus-localized GRP75 could be actively involved in the RA-
induced neuronal differentiation of NB cells by interacting with
RA receptors and modulating their activities. To investigate this
possible mechanism, the potential association between GRP75 and
RARa/RXRa in the nucleus in response to RA-induced neuronal
differentiation was investigated. Using co-immunoprecipitation, a
physical interaction between endogenous GRP75 and RARa and
RXRa in the nucleus was demonstrated. This novel interaction
between GRP75 and RARa/RXRa was significantly enhanced in
the nucleus in RA-treated NB cells compared to controls, but it
was trivial and irresponsive to RA treatment in the cytosol
(Figure 1A, B). Co-immunoprecipitation with a non-specific mouse
IgG did not reveal any detectable interaction between GRP75 and
RA receptors (Figure S11). Moreover, the co-localization of
GRP75 with RARa/RXRa heterodimers was vividly observed in
the nucleus of RA-treated SH-SY5Y cells and increased upon RA
stimulation (Figure 1C-F, Figure S2), suggesting that RA could
selectively and significantly enhance the binding of GRP75 to
RARa/RXRa. The interaction between GRP75 and RARa/
RXRa was independently validated in two MYCN-nonamplified
(SK-N-SH and SK-N-MC) and three MYCN-amplified NB cell
lines (SK-N-DZ, SK-N-BE, and IMR-32) (Figure S3), suggesting a
critical role of GRP75 in RA signaling and NB differentiation.
Together, these results strongly suggest that GRP75 participates in
RA-elicited neuronal differentiation of NB cells through its direct
interaction with nuclear RARa/RXRa heterodimers.
Down-regulation of GRP75 inhibits RA-elicited activation
of RARa/RXRa receptors
To determine whether the binding of GRP75 to the RARa/
RXRa receptor complex in the nucleus is necessary for the RA-
induced neuronal differentiation of NB cells, the expression of RA
target genes was examined in GRP75-deficient SH-SY5Y cells in
the presence or absence of RA. Using an RARa/RXRa-driven
luciferase reporter gene construct (RARE-Luc), RA-induced
reporter gene expression was determined to be abrogated by the
down-regulation of GRP75, suggesting that GRP75 is required for
RA-triggered transcriptional regulation (Figure 2A). This finding
was further corroborated by data showing that GRP75-deficient
SH-SY5Y cells exhibit a significant reduction in the RA-elicited
activation of the RARb promoter, a known RARa/RXRa
downstream target gene [18] (Figure 2B). The knockdown
efficiency of both GRP75-targeting shRNAs was approximately
75%, as seen in the mRNA transcript and protein levels (Figure 2E
and Figure S4). Using reporter gene constructs derived from
MYCN and NEDD9 promoters [19,20], the depletion of GRP75
in SH-SY5Y cells was further demonstrated to effectively inhibit
the RA-elicited stimulation of NEDD9 promoter activity (a
neuronal differentiation marker) and abolish the RA-triggered
suppression of MYCN promoter activity (a proliferation marker)
(Figures 2C, D). The present data clearly suggest that GRP75
could be a novel transcriptional coactivator of RARa/RXRa and
therefore modulate RA-elicited neuronal differentiation of NB
cells.
To further substantiate the role of GRP75 in RARa/RXRa-
mediated transcriptional regulation, the mRNA transcript levels of
selected RA target genes were examined by real-time quantitative
PCR. Several RA target genes, such as CLMN, CRABP2,
HOXD10, RARb, NAV2, NEDD9, RET, TH, and TrkA, have
been shown to promote neuronal differentiation, whereas others,
including MYCN, Survivin, and p34, function in cell proliferation
[19,21,22,23,24]. In the present study, while the expression of nine
RA target genes involved in neuronal differentiation was
significantly elevated in RA-treated NB cells compared to controls,
knockdown of GRP75 dramatically compromised the RA-induced
transcriptional up-regulation of these pro-differentiation target
genes in NB cells (Figure 2G). Concomitant with defective
neuronal differentiation, down-regulation of GRP75 could favor
cell growth by diminishing the RA-elicited transcriptional
suppression of pro-proliferation target genes (MYCN, Survivin,
and p34) (Figure 2F).
Consistent with the essential role of GRP75 in neuronal
differentiation, the ectopic expression of GRP75 in SH-SY5Y
cells significantly enhanced RA-triggered transactivation of
RARa/RXRa (Figure 3A-C). The GRP75-dependent transcrip-
tional regulation of RA target genes was further explored through
the ectopic expression of GRP75 in SH-SY5Y cells. Overexpres-
sion of GRP75 significantly potentiated the expression of
differentiation-promoting genes and suppressed the expression of
pro-proliferation genes in NB cells with or without RA (Figure 3E,
F). Together, the regulation of RA-elicited neuronal differentiation
by GRP75 was independently confirmed in separate albeit related
NB cell lines SH-SY5Y and SK-N-SH (Figure 2, Figure 3, Figure
GRP75 Promotes RA-Induced Neuronal Differentiation
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26236Figure 1. Nuclear GRP75 physically interacts with RARa/RXRa in differentiated NB cells. (A and B) Nuclear and cytoplasmic extracts were
prepared from SH-SY5Y cells treated with RA (10 mM) or vehicle alone (0.1% DMSO) for various intervals. Clarified lysates of treated cells were
subjected to immunoprecipitation using anti-GRP75 antibodies, followed by Western blot analysis with anti-RARa or RXRa. The levels of
immunoprecipitated nuclear RARa and RXRa were normalized with those of nuclear GRP75 from the same immunopreciptate. The ratio of RARa or
RXRa to GRP75 in DMSO-treated cells at a specific interval was referred to as 1 fold of relative interaction. Quantitative results are shown as the mean
interactions of GRP75 with RARa or RXRa (6SEM) of three individual experiments and were analyzed by Student’s t test. *p,0.05. (C-F)
Immunofluorescence staining representing the colocalization between GRP75 and RARa/RXRa. SH-SY5Y cells were treated with RA (10 mM) or vehicle
alone (0.1% DMSO) for 3 d and processed for immunofluorescence staining with anti-MAP2, anti-GRP75, and either anti-RARa or RXRa. Nuclei were
visualized by DAPI counterstaining. Three-dimensional analysis of the co-localization of GRP75 and either RARa or RXRa by z-stack images was
denoted by intersecting lines in the x, y, and z axes. Scale bar=20 mm. Overlapped pixels (yellow) corresponding to GRP75 (green) and either RARa (C,
red) or RXRa (E, red) were defined as the co-localization of GRP75 with either RARa or RXRa. The co-localization of GRP75 with either RARa (D) or
RXRa (F) was determined as the mean (6SEM) percentages of nuclear GRP75-specific pixels overlapped with either RARa- or RXRa-specific pixels from
at least three different viewing areas per experiment in three independent experiments and analyzed by Student’s t test. *p,0.05.
doi:10.1371/journal.pone.0026236.g001
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PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26236Figure 2. GRP75 is required for the transcriptional regulation of RA target genes in NB cells. (A–D) SH-SY5Y cells were infected with
lentivirus encoding shRNA targeting GFP (Control-sh) or GRP75 (GRP75-sh-1 and -2) for 2 d, and infected cells were then transfected with RARE-Luc
(A), RARb promoter-Luc (B), NEDD9-Luc (C), or the MYCN-Luc (D) reporter gene construct for an additional 2 d. Following treatment with RA (10 mM)
or vehicle alone (0.1% DMSO) for 24 h at 37uC, the luciferase signals in clarified lysates of treated cells were determined and normalized to protein
concentration. Normalized luciferase signal of DMSO-treated Control-sh-infected cells were referred to as one fold of relative luciferase activity. (E)
shRNA-infected SH-SY5Y cells treated with RA or DMSO as described above were harvested and processed for total RNA isolation by TRIzol reagent.
The levels of GRP75 mRNA transcript as well as GAPDH (internal control) were determined by real-time RT-PCR. The normalized level of GRP75
transcript in Control-sh-infected DMSO-treated cells was referred to as 1 fold of relative GRP75 expression. Quantitative data were calculated as the
mean (6SEM) relative GRP75 expression of triplicate measurements from three independent experiments and analyzed by Student’s t test. (F-G) Total
RNA transcripts of shRNA-infected SH-SY5Y cells treated with RA or DMSO were analyzed by real-time RT-PCR for the expression of RA target genes
essential for cell proliferation (F) and neuronal differentiation (G). All quantitative data were calculated as the mean (6SEM) from three independent
experiments and analyzed by Student’s t test. *p,0.05.
doi:10.1371/journal.pone.0026236.g002
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PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e26236Figure 3. Overexpression of GRP75 augments RA-elicited activation of RARa/RXRa-mediated transcriptional regulation in SH-SY5Y
cells. (A) SH-SY5Y cells were transiently transfected with an empty vector or a GRP75-expression vector for 24 h. Ectopic expression of GFP-GRP75 in
RA-treated transfected cells was analyzed by Western blot analysis with anti-GFP antibody (upper panel, for GRP75). GAPDH (lower panel) was used as
a protein loading control. (B and C) SH-SY5Y cells were transiently co-transfected with a RA-responsive reporter gene construct (2 mg of RARE-Luc or
GRP75 Promotes RA-Induced Neuronal Differentiation
PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26236S9, and Figure S10). The present results clearly demonstrate for
the first time that GRP75 can be actively involved in RARa/
RXRa-mediated transcriptional regulation in RA-triggered neu-
ronal differentiation of NB cells.
GRP75/RARa/RXRa complexes cooperatively bind to the
retinoic acid response element (RARE) within the
promoters of RA-responsive genes
To further demonstrate the functional role of the GRP75-bound
RARa/RXRa receptor complex in RA-elicited transcriptional
regulation, the RARa/RXRa-mediated binding to DR5 RARE
within the promoter of RARb, a direct target gene downstream of
RA-elicited signaling [18], was examined using chromatin
immunoprecipitation (ChIP) in SH-SY5Y cells infected with
lentiviral particles expressing shRNAs targeting GFP (Control-sh)
or GRP75 (GRP75-sh-1 and GRP75-sh-2) in the presence or
absence of RA. The RNAi-mediated down-regulation of GRP75
significantly diminished the recruitment of RARa and RXRa
receptors to RARE-containing promoter regions in RA-treated
NB cells (Figure 4A), suggesting that GRP75 can be recruited to
RARE consensus sequence within the promoter of RARb and
indispensable for the binding of RARa/RXRa receptor complex-
es to the promoters of RA target genes and that it critically
modulates the RA-elicited expression of pro-differentiation genes.
Since GRP75, RARa, and RXRa are all indispensable for cell
viability, the depletion of GRP75 in SH-SY5Y cells in the absence
of RA could compromise the basal viability of NB cells [9,25,26].
It is thus possible that the recruitment of RARa/RXRa to the
RARE region could be enhanced to compensate the loss in
GRP75-dependent maintenance of cell viability in response to
GRP75 knockdown. These findings thus favor a model in which
the binding of GRP75 is a prerequisite for the efficient association
of RARa/RXRa complexes with RARE-containing promoter
regions to modulate the expression of RA target genes in the
regulation of neuronal differentiation.
Down-regulation of GRP75 promotes RARa/RXRa
degradation through a proteasome-mediated pathway
Accumulated evidence also suggests that the ubiquitin protea-
some system (UPS)-mediated degradation and the binding to
molecularchaperonescanmodulatetheactivityofsteroid receptors,
including RAR/RXR retinoid receptor family [27,28,29,30]. We
thus demonstrated that RNAi-mediated down-regulation of GRP75
in RA-treated SH-SY5Y cells resulted in a significant increase in the
ubiquitination and UPS-mediated degradation of ligand-bound
RARa/RXRa, compared to mock-infected cells (Figure 5). Con-
sistent with its protective role, the overexpression of GRP75 resulted
in a significant attenuation in the ubiquitination of both RARa and
RXRa (Figure S5). Together, these findings suggest that GRP75-
dependent increase in the stability of ligand-bound RARa/RXRa
heterodimers could selectively potentiate ligand-bound RARa/
RXRa-mediated transcriptional regulation, synergistically aug-
menting RA-elicited neuronal differentiation.
An enhanced interaction between GRP75 and RARa/
RXRa heterodimers is associated with favorable
outcomes in an in vivo xenograft NB mouse model
To validate the significance of the interaction between GRP75
and RARa/RXRa heterodimers in the modulation of RA-elicited
neuronal differentiation in vivo, the correlation of these novel
protein-protein interactions with tumor progression was examined
in a xenograft NB mouse model [31]. We found that RA treatment
significantly inhibits tumor growth beginning on the fourth
treatment day until the completion of the treatment period in
comparison to vehicle-treated control animals based on tumor size
measurements. The assessment of harvested tumor xenografts at
the conclusion of treatment revealed that both tumor size and
tumor weight were significantly decreased in RA-treated mice
(Tables S1), indicating that RA therapy can effectively inhibit the
progression of NB. The correlation between the level of GRP75/
RARa/RXRa tripartite complexes and tumor growth was further
analyzed in the harvested NB xenografts. Our data showed that
the association of GRP75 with either RARa or RXRa is
significantly increased in RA-treated xenografts compared to
controls (Figure 6, Table S1). Linear correlation analysis
demonstrated that the formation of either GRP75/RARa or
GRP75/RXRa complexes was markedly elevated in tumors with
reduced volume or weight (RA-treated xenografts), in stark
contrast to the control tumors with larger volume or weight
(Figure S6). These results clearly demonstrate that the complex
formation of tripartite GRP75/RARa/RXRa is inversely corre-
lated with the progression of NB.
The interaction between GRP75 and RXRa/RARais
correlated with a higher grade of histological
differentiation and a normal MYCN copy number in
human NB tumors
To corroborate the relationship between the RA-induced
formation of nucleus-localized GRP75/RARa/RXRa tripartite
complexes with the differentiation of human NB, the interaction
between GRP75 and RARa/RXRa heterodimers was examined
in NB tumors with various grades of histological differentiation.
Using co-immunoprecipitation with an anti-GRP75 antibody and
lysates derived from 30 human NB tumors, including 13
ganglioneuroblastomas (GNBs), 9 differentiating NBs (DNBs),
and 8 undifferentiated NBs (UNBs), the interaction between
GRP75 and RARa/RXRa was found to be significantly stronger
in tumors with higher grades of histological differentiation (GNB
and DNB) than in those with an undifferentiated histology (UNB)
(Figure 7A, B and Figure S8). Furthermore, the interaction
RARb-Luc) and a GRP75-expressing construct at various concentrations for 24 h, followed by treatment with 10 mM RA for 24 h. Luciferase signals
derived from reporter gene constructs were determined by Steady-Glo luciferase assay reagents and normalized by protein concentration. The
normalized luciferase signal in DMSO-treated cells transfected with an empty vector alone was referred to as 1 fold of relative luciferase activity.
Quantitative results are presented as the mean (6SEM) of triplicate measurements from three independent experiments and were analyzed by
Student’s t test. *p,0.05. (D) The levels of GRP75 mRNA transcripts in SH-SY5Y cells transiently transfected with a GRP75-expressing vector were
determined by quantitative real-time RT-PCR. The normalized level of GRP75 transcripts in DMSO-treated cells transfected with an empty vector alone
was referred to as 1 fold of relative expression. Quantitative results are presented as the mean (6SEM) of triplicate measurements from three
independent experiments. (E and F) SH-SY5Y cells were transfected with an empty vector or a GRP75-expressing vector for 48 h, followed by
treatment with or without RA for 24 h. The transcript levels of various RA-responsive genes in transfected cells were determined by quantitative real-
time RT-PCR. The normalized transcript level in DMSO-treated cells transfected with an empty vector alone was referred to as 1 fold of relative
expression. Quantitative results are presented as the mean (6SEM) of triplicate measurements from three independent experiments and were
analyzed by Student’s t test.
doi:10.1371/journal.pone.0026236.g003
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normal MYCN copy number compared with those with MYCN
amplification which carry a very unfavorable prognosis (Figure 7C,
D). These pieces of evidence were consistent with our finding that
GRP75 is required for RA-elicited down-regulation of MYCN
expression (Figure 2D, F). The present data thus unequivocally
support a model in which the level of tripartite GRP75/RARa/
RXRa complexes in NB tumors is tightly associated with the
histological grade of differentiation and, possibly, a favorable
prognosis of NB tumors. Our data thus favors a model in which,
upon RA-induced neuronal differentiation, GRP75 could be
recruited to the ligand-bound RARa/RXRa heterodimers to
cooperatively regulate the expression of RA downstream genes
and avert UPS-mediated degradation of RA-bound RARa/
RXRa (Figure S7A). Given that the molecular structure of human
GRP75 has not been resolved, we then based on the structure of
Escherichia coli HSP70 chaperone chain A (PubMed accession
P0A6Y8, Protein Data Bank code 2KHO_A) that exhibits the
highest amino acid sequence identity to human GRP75 to predict
the three-dimensional model of GRP75. We then further
simulated the possible docking of modeled GRP75 structure to
known RARa or RXRa structure. This molecular simulation
predicted that GRP75 could bind to the ligand-binding domain or
the DNA-binding domain of RARa/RXRa heterodimers (Figure
S7B, C). In conclusion, the present findings further strengthen the
prognostic value of the expression level of GRP75 in NB [16], and
delineate the mechanism underlying the GRP75-dependent
regulation of RA-elicited RARa/RXRa-dependent neuronal
differentiation.
Discussion
GRP75 has been shown to bind multiple partner proteins to
govern diverse cellular functions [14,32]. The alteration in the
cellular distribution of GRP75 could also correlate with the status
of cellular immortality [33,34]. Consistent with this notion, our
data clearly show that the association of GRP75 with RARa and
RXRa is remarkably increased in the nucleus and coincides with
the RA-elicited growth arrest, concomitant with a tight correlation
between RA-induced nuclear translocation of GRP75 and RA-
triggered neuronal differentiation. These data strongly favor a
model in which nuclear GRP75 could stably form complexes with
RARa/RXRa heterodimers and actively participate in RA-
triggered neuronal differentiation of NB cells through the
persistent modulation of RARa/RXRa activity (Figure S7).
The present data provide the first direct evidence that nucleus-
localized GRP75 is essential for RARa/RXRa-mediated tran-
scriptional regulation and that the GRP75/RARa/RXRa
tripartite complexes physically bind to RARE to modulate the
expression of RA target genes for neuronal differentiation
(Figures 2, 3, 4). These results also support previous findings
showing that RA-elicited down-regulation of MYCN expression is
a prerequisite for the neuronal differentiation of NB cells, while
constitutive overexpression of MYCN can counteract RA-induced
neuronal differentiation [35,36]. GRP75 could thus play a central
role in coordinating the transcriptional regulation of MYCN
expression through the stimulation of RARa/RXRa activity,
modulating a positive auto-regulatory loop for MYCN in NB cells
[20]. GRP75 could also act as a transcriptional co-activator to
potentiate RARa/RXRa-mediated transactivation of pro-differ-
entiation genes, constituting a positive feedback loop that can
potentiate RA-induced neuronal differentiation of NB cells.
Consistent with the essential role of GRP75 in neuronal function
[37], our results thus strengthen the notion that the functions of
retinoid receptors, like other nuclear receptors, could be regulated
by molecular chaperones, such as GRP75, in an evolutionarily
conserved fashion [38,39,40].
The activity of nuclear receptors could be regulated by post-
translational modifications, including phosphorylation and ubiqui-
tination [41]. Previous studies have shown that phosphorylation of
Figure 4. GRP75 is an obligatory constituent of RARa/RXRa-containing transcription machinery. (A) Down-regulation of GRP75 reduces
the RA-elicited binding of RARa/RXRa heterodimers to the RARE motif. SH-SY5Y cells were infected by a lentivirus expressing control shRNA (Control-
sh) or GRP75-targeting shRNAs (GRP75-sh-1 and -2) for 2 d. Infected cells were grown in the presence or absence of RA (10 mM) for 24 h. Soluble
chromatins of treated cells were cross-linked by formaldehyde and sonicated to shear DNA. Protein-bound chromatin fragments were
immunoprecipitated using a control mouse IgG antibody, mouse anti-GRP75, rabbit anti-RARa, or rabbit anti-RXRa antibody. The levels of DR5 RARE
sequences within the RARb promoter eluted from antibody-reactive immunoprecipitates were determined by quantitative real-time PCR. Sonicated
total DNA fragments were used as the input DNA. The level of DR5 RARE normalized with input DNA in control IgG-reactive immunoprecipitates
derived from DMSO-treated Control-sh-infected cells was referred to as one fold of relative occupancy. The results are shown as the mean (6SEM)
from three independent experiments and were analyzed by Student’s t test. p,0.05.
doi:10.1371/journal.pone.0026236.g004
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mediated embryonic development and underlies the pathogenesis
of xeroderma pigmentosum [42]. RARs have also been shown to
interact with SUG-1 to induce its ubiquitination and degradation
by the proteasome upon RA stimulation [43]. A recent study
revealed that Hsp27 can form a complex with androgen receptor
(AR) and co-migrate into the nucleus to modulate the transcrip-
tional activity of AR through an alteration in the UPS-mediated
degradation of AR [28]. The activity of RA receptors was also
shown to be modulated by interacting proteins, such as calreticulin
[44]. Consistent with the functional roles of chaperones [45], the
present results showing that GRP75 interacts with RARa and
RXRa and is involved in the UPS-mediated degradation of these
receptors further substantiate the idea that the magnitude and
function of retinoid-elicited signaling could depend on the
efficiency of the UPS-mediated processing of ligand-bound
retinoid receptors (Figure 5 and Figure S5). A recent study
showed that the molecular chaperone HSP90 binds to the E3
ubiquitin ligase CHIP and prevents CHIP-mediated degradation
of leucine-rich repeat kinase 2 (LRRK2) [46]. The present findings
that GRP75 could stabilize the RARa/RXRa complex by
modulating the UPS pathway to potentiate the RA-elicited
Figure 5. Deficiency in GRP75 promotes the degradation of RARa/RXRa heterodimers by the ubiquitin proteasome system. (A and B)
SH-SY5Y cells were infected with a control shRNA (Control-sh) or GRP75-specific shRNAs (GRP75-sh-1 and -2) for 2 d. Cells were then treated with
50 mg/ml of cycloheximide (CHX) and 10 mM RA for various intervals. The protein levels of RARa, RXRa, GRP75, and GAPDH (protein load control) were
analyzed by SDS-PAGE and immunoblotting (A). The relative levels of RARa (left panel) and RXRa (right panel) in infected cells prior to being treated
with cycloheximide and RA were referred to as 100% (B). (C and D) SH-SY5Y cells infected with gene-targeting lentiviral shRNAs (Control-sh, GRP75-
sh-1, and GRP75-sh-2) were treated with MG-132 (5 mM) in the presence or absence of RA (10 mM) for 16 h. Clarified lysates were subjected to
immunoprecipitation with either anti-RARa or anti-RXRa. The ubiquitinated RARa (C) and RXRa (D) in immunoprecipitates were resolved by SDS-
PAGE and visualized by immunoblotting with an anti-ubiquitin antibody. The same blots were reprobed with anti-RARa or anti-RXRa to reveal the
input levels of both receptors (lower panel).
doi:10.1371/journal.pone.0026236.g005
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PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e26236Figure 6. The interaction between GRP75 and RARa/RXRa is significantly increased in mouse NB xenografts treated with RA. Male
nude mice were subcutaneously inoculated with 1610
7 stNB-V1 NB cells with matrigel. Once the size of the xenograft tumor reached approximately
1c m
3, tumor-bearing mice were intraperitoneally treated with RA (1 mg/kg b.w.) or vehicle (0.1% DMSO) daily for 14 d. Clarified lysates derived from
xenograft tumors were subjected to immunoprecipitation with an anti-GRP75 antibody. Immunoprecipitated proteins were analyzed by SDS-PAGE
and immunoblotting with anti-RARa (A) or RXRa (B). The same blots were reprobed with anti-GRP75 to reveal the input level of GRP75 (lower panel).
The ratios of RARa to GRP75 (A) and RXRa to GRP75 (B) were referred to as the interaction between GRP75 and respective receptors. Quantitative
results are shown as the mean (6SEM) of 8 xenografts from two independent experiments and were analyzed by Student’s t test. *p,0.05.
doi:10.1371/journal.pone.0026236.g006
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PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e26236neuronal differentiation of NB cells further support a critical role
of the UPS pathway in the regulation of the activity of RA
receptors [47].
The association between GRP75 and RARa/RXRa heterodi-
mers is of clinical significance. In a xenograft mouse model of NB
and a cohort of patient samples, the formation of tripartite
GRP75/RARa/RXRa complexes was inversely correlated with
tumor progression and consistently predicted a favorable outcome
(Figure 6, Figure 7, Figure S6, and Table S1). Given that the N-
terminal ATP-binding domain and the C-terminal substrate-
binding domain of GRP75 are highly identical to those of human
Hsp70 [48,49], GRP75 could act like Hsp70 and modulate the
conformations of RARa and RXRa. Based on the molecular
modeling for the interaction between GRP75 and either RARa or
RXRa (Figure S7), GRP75 is likely to interact with either the
ligand-binding domain or the DNA-binding domain of RARa/
RXRa heterodimers to synergistically stabilize the RA-bound
GRP75/RARa/RXRa complexes and sustain their transcription-
al activation. Synthetic molecules designed to either induce the de
novo formation of GRP75/RARa/RXRa complexes or stabilize
the pre-existent ones could thus have profound therapeutic
implication for NB.
In summary, the present study identifies a novel function of
GRP75 in regulating RA-elicited neuronal differentiation through
direct interaction with RARa/RXRa heterodimers in the nucleus.
The elucidation of the molecular mechanism involved in the
formation of tripartite GRP75/RARa/RXRa complexes provides
the basis for the development of a novel therapeutic strategy for
NB that could be combined with other existing differentiating
regimens to improve the overall outcomes of NB patients [50,51].
Our data could serve as the foundation for the generation of
molecules that could simultaneously prevent UPS-mediated
degradation of RARa/RXRa and extend the pro-differentiation
effect of GRP75/RARa/RXRa complexes.
Materials and Methods
Ethics Statement
The Institutional Review Board of National Taiwan University
Hospital approved the complete follow-up protocols and this
study. We obtained the written informed consent from all
participants involved in this study. The animal study protocol
used in this study was approved by the Institutional Animal Care
and Use Committee of Academia Sinica (Approval Protocol ID
Figure 7. The interaction between GRP75 and RARa/RXRa in primary NB tumors is tightly associated with the differentiation
histology but is inversely correlated with MYCN amplification. (A and B) Tumors collected from NB patients with different histology statuses,
including ganglioneuroblastoma (GNB), differentiated neuroblastoma (DNB), and undifferentiated neuroblastoma (UNB), were processed for
immunoprecipitation with anti-GRP75. The levels of GRP75-interacting RARa and RXRa in immunoprecipitates were analyzed by immunoblotting
with anti-RARa (A) or anti-RXRa (B). The same blots were reprobed with anti-GRP75 to reveal the input level of GRP75. The ratios of RARa to GRP75 (A)
and RXRa to GRP75 (B) were referred to as the interaction between GRP75 and the respective receptors. Quantitative results are shown as the mean
(6SEM) interaction between GRP75 and RARa (A) or RXRa (B) and were analyzed by Student’s t test. *p,0.05. The images of Western blots for the
GRP75 immunoprecipitation used for this analysis wwer included in the Figure S8. Human NBs were classified by histology based on the criteria
established by the International Neuroblastoma Pathology Classification [53]. GNB (n=13); DNB (n=9); UNB (n=8). (C and D) The correlation
between the levels of GRP75/RARa/RXRa complexes and MYCN status in primary NB tumors from the same cohort was determined. Quantitative data
are shown as the mean (6SEM) interaction between GRP75 and RARa (C) or RXRa (D) in tumors without MYCN amplification (MYCN-nonamplified,
n=16) or those with MYCN amplification (MYCN-amplified, n=5) and were analyzed by Student’s t test. *p,0.05.
doi:10.1371/journal.pone.0026236.g007
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Invitrogen (Carlsbad, CA).
Authentication of cell lines
The human NBcelllinesSH-SY5Y (ATCCH CRL-2266
TM),SK-
N-SH (ATCCH HTB-11
TM), SK-N-DZ (ATCCH CRL-2149
TM),
SK-N-MC (ATCCH HTB-10
TM), and SK-N-BE(2) (ATCCH CRL-
2271
TM) were obtained from American Type Culture Collection
(Manassas, VA, USA) in November 2007. The human NB cell line
IMR-32 (BCRC 60014) was obtained from Biosource Collection
and Research Center (Hsinchu, Taiwan) in November 2007. These
NB cell lines have been authenticated in our laboratory in a monthly
basis.TheSH-SY5Yand SK-N-SHcelllineswere lastauthenticated
by microscopic morphology check and PCR-based microplasma test
inAugust2011.ThePCR-basedmicroplasmatestingwasperformed
as previously described [50].
Immunofluorescence confocal microscopy
SH-SY5Y cells were grown on coverslips and treated with
10 mM RA in DMSO or 0.1% DMSO alone for the indicated
time. Immunofluorescence staining was performed as described
previously [16].
Reporter gene constructs and lentiviral shRNAs
The DR5-TK and RARb-luciferase reporter constructs were
kindly provided by Dr. Jonathan Kurie (The University of Texas
M.D. Anderson Cancer Center) [52]. The Nedd9 promoter
constructs were kindly provided by Dr. Margaret Clagett-Dame
(University of Wisconsin-Madison) [19]. The shRNA lentiviral
vectors targeting human GRP75 (GRP75-sh-1 and GRP75-sh-2)
and a GFP-targeting control lentiviral vector (Control-sh) were
purchased from the National RNAi Core Facility, Academia
Sinica, Taiwan.
Co-immunoprecipitation and Western blotting
The nuclear extracts and cytosolic pools of treated cells were
isolated using the Nuclei EZ Prep Kit (Sigma) as described in the
manufacturer’s instructions. For co-immunoprecipitation, 20 mgo f
goat anti-GRP75 antibody was incubated with 200 mlo f
immobilized protein A agarose in PBS for 2 h at 4uC.
Immunoprecipitated proteins were eluted by the addition of 4X
sample loading buffer and boiling at 100uC for 10 min, followed
by SDS-PAGE and Western blotting.
Luciferase reporter assay
shRNA-transduced cells were transfected with a promoter-
specific luciferase reporter gene construct (either RARE-luc,
RARb-luc, NEDD9-luc, or MYCN-luc) using Lipofectamine
2000 at 37uC overnight. Promoter-driven luminescence in the
clarified lysates of transfected cells was determined using the
Steady-Glo luciferase assay reagent (Promega) and normalized to
the protein content of the lysates.
RNA isolation, reverse transcription, and quantitative
real-time PCR
Total RNA was isolated from transduced SH-SY5Y cells
using the TRIzol Reagent (Invitrogen). Purified RNAs (2 mg)
were reverse-transcribed to the first-strand cDNA using the
SuperScript III First-strand cDNA Synthesis Kit (Invitrogen).
Equivalent amounts of cDNA were used in quantitative real-
time PCR using the SYBR Green I Master reagent on the
LightCycler 480 Real-Time PCR System (Roche) with gene-
specific primer pairs.
Chromatin immunoprecipitation (ChIP)
Treated cells were fixed with 1% formaldehyde for 10 min at
37uC, and the reaction was terminated by the addition of 1.25 M
glycine (1:9, v/v). Fixed cells were lysed and sonicated in buffer A
(1% SDS, 10 mM EDTA, 50 mM Tris, pH 8.0) to shear DNA.
Clarified lysates were subject to immunoprecipitation using
antibodies (10 mg) against either GRP75, RARa, RXRa,o r
mouse IgG (as control) at 4uC overnight with agitation, followed
by incubation with protein A-conjugated agarose at 4uC for 1 h.
Protein stability
Protein synthesis in infected cells was inhibited with 50 mg/ml
cycloheximide for 3 h, followed by the addition of 10 mMR Ao r
vehicle alone (0.1% DMSO) and incubation at 37uC for various
intervals.
Ubiquitination assay for RARa and RXRa
SH-SY5Y cells were infected with GRP75-sh-1, GRP75-sh-2, or
control-sh at 37uC for 2 d, followed by the removal of infection
mixture and incubation with fresh medium containing 10 mMR A
or 0.1% DMSO for 16 h in the presence or absence of 5 mM
MG132.
Patients and sample preparation
A cohort of 30 histologically confirmed NB patients with
complete follow-up protocols approved by the Institutional Review
Board of National Taiwan University Hospital, Taipei, Taiwan,
were enrolled in this study. The Institutional Review Board of
National Taiwan University Hospital also approved this study, and
we obtained informed written consent from all participants
involved in this study. Tumor samples were obtained during
surgery and immediately frozen in liquid nitrogen. The catego-
rization of tumor biopsies was based on the International
Neuroblastoma Pathology Classification scheme [53].
Additional information regarding details of individual experi-
mental procedures can be found in the Supplemental Methods S1
submitted along with the main manuscript.
Supporting Information
Figure S1 GRP75 is translocated into the nucleus of
differentiated neuroblastoma cells. (A) Immunofluores-
cence microscopy analysis of GRP75 in the nuclei of NB cells.
SH-SY5Y cells were treated with or without RA (10 mM) for 3 d
and processed for immunofluorescence staining with an anti-
GRP75 antibody (green). Nuclei were counterstained with DAPI
(blue). Insets, two-fold magnification of highlighted cells (arrow).
Scale bar=20 mm. (B) Three-dimensional analysis of individual
cells by z-stack confocal images at specific sites marked by
intersecting lines in the x, y, and z axes. (C) Quantitative analysis of
the intensity of cells double labeled for GRP75 and DAPI (nuclear
DNA). Data are expressed as the average percentage (6SEM) of
nuclear GRP75 co-localized with RARa from three independent
experiments. *p,0.05. (D) The nuclear extracts of SH-SY5Y cells
treated with or without RA for various intervals were resolved by
SDS-PAGE and analyzed by immunoblotting with the indicated
antibodies. Histone H1 and Lamin A/C were markers for nuclear
extracts, while GAPDH was included as a protein loading control
for cytosolic pools. The prolonged exposure for GAPDH blot
(Nucleus) revealed no contamination of cytosolic proteins in the
isolated nuclear extracts. Similarly, overexposure of histone H1-
and lamin A/C-labeled blots (Cytosol) showed that isolated
cytosolic pools were free from contamination of nuclear proteins.
(TIF)
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RXRa is increased in RA-treated SH-SY5Y cells. (A) SH-
SY5Y cells were grown on coverslips and treated with 10 mMR A
for various intervals. Cells treated with vehicle alone (0.1%
DMSO) were included as controls. Treated cells were fixed with
4% paraformaldehyde and subjected to immunofluorescence
staining using goat anti-GRP75 (green), mouse anti-MAP2 (red),
and rabbit anti-RARa (red). Nuclei were counterstained with
DAPI. The inset shows the magnification of the highlighted region
(arrow). Scale bar=20 mm. (B) The levels of nuclear GRP75 were
quantified using MetaMorph Offline 7.5.1.0 Image Analysis
System (Molecular Devices). Quantitative results are shown as
the mean (6SEM) from three independent experiments. (C) The
levels of GRP75 co-localized with RARa in the nucleus were
quantified using the MetaMorph Offline 7.5.1.0 Image Analysis
System (Molecular Devices). Quantitative data are shown as
means (6SEM) of at least three different viewing areas from three
independent experiments. All quantitative data were analyzed by
Student’s t test. *p,0.05 versus DMSO-treated control (– RA). (D)
SH-SY5Y cells were treated with 10 mM RA for various intervals.
Cells treated with vehicle alone (0.1% DMSO) were included as
controls (– RA). Treated cells were fixed with 4% paraformalde-
hyde and subjected to immunofluorescence staining using goat
anti-GRP75 (green), mouse anti-MAP2 (red), and rabbit anti-
RXRa (red). Nuclei were visualized by DAPI staining. The inset
shows the magnified view of the highlighted region (arrow). Scale
bar=20 mm. (E and F) The levels of nuclear GRP75 (E) and
RXRa-co-localized GRP75 in the nucleus (F) were determined
using the MetaMorph Offline 7.5.1.0 Image Analysis System
(Molecular Devices). Quantitative results are shown as means
(6SEM) from three independent experiments and were analyzed
by Student’s t test. *p,0.05 versus DMSO-treated control (– RA).
The number of cells used in the quantitative analysis was at least
150.
(TIF)
Figure S3 RA enhances the formation of GRP75/RARa/
RXRa tripartite complexes in various NB cell lines.
MYCN-nonamplified NB cell lines, including SK-N-SH (A), SK-
N-MC (B), and stNB-V1 (C), and MYCN-amplified NB cell lines,
including SK-N-BE (D), SK-N-DZ (E), and IMR-32 (F), were
treated with 10 mM RA or vehicle alone (0.1% DMSO) for 1 d.
Nuclear lysates were immunoprecipitated with a mouse anti-
GRP75 antibody. Protein A-bound antigen-antibody complexes
were analyzed by immunoblotting with anti-RARa (upper panel),
anti-RXRa (middle panel), or anti-GRP75 (lower panel, loading
control). The levels of RARa and RXRa were normalized to
GRP75 from the same immunoprecipitate, and those in cells
without RA treatment were referred to as one fold of relative
interaction between GRP75 and respective RA receptors (RARa
and RXRa).
(TIF)
Figure S4 Lentiviral shRNA-mediated down-regulation
of GRP75 in SH-SY5Y cells. SH-SY5Y cells were infected with
lentiviral shRNA targeting GFP (Control-sh) or GRP75 (GRP75-
sh-1 and -2) for 2 d, followed by treatment with 10 mMR Ao r
vehicle alone (0.1% DMSO) for 1 d. Clarified lysates containing
equivalent amounts of proteins were analyzed by Western blotting
with anti-GRP75 (upper panel) or GAPDH (lower panel, protein
load control).
(TIF)
Figure S5 Overexpression of GRP75 in SH-SY5Y cells
decreases the ubiquitination of RARa and RXRa in
response to RA signaling. SH-SY5Y cells were transiently
transfected with an GRP75-expressing vector or an empty vector
for 48 h, followed by treatment with 10 mM of MG132 in the
presence or absence of 10 mM RA for an additional 16 h. Clarified
lysates were subjected to immunoprecipitation with a rabbit anti-
RARa (A) or anti-RXRa (B) antibody. Proteins pulled down by
immunoprecipitation were resolved by SDS-PAGE and analyzed
by immunoblotting with an anti-ubiquitin antibody. The same
blots were stripped and re-probed with anti-RARa (A, lower
panel) or anti-RXRa (B, lower panel) to visualize the individual
receptors as loading controls.
(TIF)
Figure S6 The interaction between GRP75 and RARa/
RXRa heterodimers was inversely correlated to tumor
volume and tumor weight in a xenograft NB mouse
model. The interaction between GRP75 and RARa/RXRa in
xenograft NB tumors harvested from mice treated with RA (solid
bar) or saline (open bar) was determined as described in Fig. 6 of
the main text. The ratio of RARa to GRP75 (A) or RXRa to
GRP75 (B) in individual xenografts was normalized to tumor
volume (left panel) or tumor weight (right panel). Quantitative
results are shown as the means (6SEM) from xenografts in
controls (no treatment, n=8) or treated animals (RA treatment,
n=8) and were analyzed by Student’s t test. *p,0.05.
(TIF)
Figure S7 A model delineating the GRP75-mediated
regulation of RA-elicited neuronal differentiation
through direct interaction with RARa/RXRa and the
structure modeling predicting interaction interfaces
between GRP75 and RARa/RXRa. (A) The model illustrates
that GRP75 could act as a cofactor of RARa/RXRa to mediate
RA-triggered neuronal differentiation. Upon RA stimulation,
GRP75 could be recruited to the ligand-bound RARa/RXRa
heterodimers and cooperatively regulate the expression of RA
downstream genes, resulting in enhanced neuronal differentiation.
Simultaneously, RA-bound GRP75/RARa/RXRa tripartite
complexes could avert UPS-mediated degradation, extending the
RA-elicited transactivation of RARa/RXRa to induce neuronal
differentiation. (B and C) Structure modeling predicts that GRP75
could bind to the ligand-binding domain (B) or the DNA-binding
domain (C) of RARa/RXRa heterodimers. White, GRP75;
Green, RARa; Blue, RXRa; Yellow and pink, double strand
DNA.
(TIF)
Figure S8 The binding of GRP75 to RARa or RXRa is
elevated in NB patients with favorable outcome. The
levels of GRP75/RARa/RXRa complexes in 30 primary tumors
with various histologies was analyzed by immunoprecipitation
with a mouse anti-GRP75 antibody, followed by immunoblotting
with indicated antibodies. Corresponding quantitative analysis of
these blots was shown in the Figure 7 of main text. GNB,
ganglioneuroblastoma (n=13, G1,G13); DNB, differentiated
neuroblastoma (n=9, D1,D9); UNB, undifferentiated neuroblas-
toma (n=8, U1,U8).
(TIF)
Figure S9 Down-regulation of GRP75 abrogates RA-
elicited transcriptional activation of RA receptors in SK-
N-SH cells. (A–D) SK-N-SH cells were infected with lentivirus
encoding shRNA targeting GFP (Control-sh) or GRP75 (GRP75-
sh-1 and -2) for 2 d. The knockdown efficiency was verified by
immunoblotting (A) or real-time RT-PCR (inset in F). For
promoter assay, the infected cells were additionally transfected
with RARE-Luc (B), RARb promoter-Luc (C), NEDD9-Luc (D), or
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Following treatment with RA (10 mM) or vehicle alone (0.1%
DMSO) for 24 h at 37uC, the luciferase signals in clarified lysates
of treated cells were determined and normalized with protein
concentration. Normalized luciferase signal of DMSO-treated
Control-sh-infected cells were referred to as one fold of relative
luciferase activity. (F-G) Infected SK-N-SH cells treated with RA
or DMSO as described above were harvested and processed for
total RNA isolation by TRIzol reagent. Total RNA transcripts of
shRNA-infected SK-N-SH cells treated with RA or DMSO were
analyzed by real-time RT-PCR for the expression of RA target
genes essential for cell proliferation (F) and neuronal differentia-
tion (G). The normalized level of GRP75 transcript in Control-sh-
infected DMSO-treated cells was referred to as 1 fold of relative
expression. All quantitative data were calculated as the mean
(6SEM) from three independent experiments and analyzed by
Student’s t test. *p,0.05.
(TIF)
Figure S10 Overexpression of GRP75 strengthens RA-
elicited activation of RA receptors in SK-N-SH cells. (A)
SK-N-SH cells were transiently transfected with an empty vector
or a GRP75-expression vector for 24 h. Ectopic expression of
GFP-GRP75 in RA-treated transfected cells was analyzed by
Western blot analysis with anti-GFP antibody (upper panel, for
GRP75). GAPDH (lower panel) was used as a protein loading
control. (B and C) SK-N-SH cells were transiently co-transfected
with a RA-responsive reporter gene construct (2 mg of RARE-Luc
or RARb-Luc) and a GRP75-expressing construct at various
concentrations for 24 h, followed by treatment with 10 mM RA for
24 h. Luciferase signals derived from reporter gene constructs
were determined by Steady-Glo luciferase assay reagents and
normalized by protein concentration. The normalized luciferase
signal in DMSO-treated cells transfected with an empty vector
alone was referred to as 1 fold of relative luciferase activity.
Quantitative results are presented as the mean (6SEM) of
triplicate measurements from three independent experiments
and were analyzed by Student’s t test. *p,0.05. (D) The levels
of GRP75 mRNA transcripts in SK-N-SH cells transiently
transfected with a GRP75-expressing vector were determined by
quantitative real-time RT-PCR. The normalized level of GRP75
transcripts in DMSO-treated cells transfected with an empty
vector alone was referred to as 1 fold of relative expression.
Quantitative results are presented as the mean (6SEM) of
triplicate measurements from three independent experiments. (E
and F) SK-N-SH cells were transfected with an empty vector or a
GRP75-expressing vector for 48 h, followed by treatment with or
without RA for 24 h. The transcript levels of various RA-
responsive genes in transfected cells were determined by
quantitative real-time RT-PCR. The normalized transcript level
in DMSO-treated cells transfected with an empty vector alone was
referred to as 1 fold of relative expression. Quantitative results are
presented as the mean (6SEM) of triplicate measurements from
three independent experiments and were analyzed by Student’s t
test.
(TIF)
Figure S11 The specificity of the mouse anti-GRP75
antibody for co-immunoprecipitation is validated in
cultured cells, tumor xenograft, and human primary
NB tumors. The cellular lysates (nuclear and cytosolic
fractions, A), homogenates derived from xenografted tumors
of mice (B), and clarified extracts derived from human primary
NB tumors with different histological grades of differentiation
(C) were immunoprecipitated with a mouse anti-GRP75 or a
mouse control IgG. The GRP75-bound proteins were analyzed
by Western blotting with a goat anti-GRP75, rabbit anti-RARa
or rabbit anti-RXRa antibody, respectively. In (C), G, gang-
lioneuroblastoma; D, differentiated neuroblastoma; U, undif-
ferentiated neuroblastoma.
(TIF)
Figure S12 RA induces nuclear translocation of GRP75
in SK-N-BE and SK-N-SH cells. SK-N-DZ (A) and SK-N-SH
(B) cells were treated with 10 mM RA for 24 h, the nuclear lysates
were subject to Western blot analysis. The levels of nuclear
GRP75 were normalized with those of histone H1. The
normalized level of GRP75 in cells without RA treatment was
referred to as one fold of relative nuclear translocation. All
quantitative data were calculated as the mean (6SEM) from three
independent experiments.
(TIF)
Figure S13 RA treatments induce the nuclear translo-
cation of GRP75 in a dose-dependent manner. SH-SY5Y
cells were treated with various concentrations of RA (0.1, 1, and
10 mM) for 24 h, and the nuclear extracts derived from treated
cells were analyzed by immunoblotting with an anti-GRP75 or
anti-histone H1 (protein loading control of nuclear fraction)
antibody. The levels of nuclear GRP75 were normalized with
those of histone H1. The normalized level of GRP75 in cells
treated with vehicle alone (0.1% DMSO) was referred to as one
fold of nuclear GRP75. All quantitative data were calculated as the
mean (6SEM) from three independent experiments.
(TIF)
Table S1 The levels of GRP75-bound RARa and RXRa in
xenografts in comparison to tumor volume and tumor weight in
mice treated with RA or vehicle.
(DOC)
Methods S1 Additional information regarding details of indi-
vidual experimental procedures.
(DOC)
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